Skip to content

Study · Randomized controlled trial · n = 17 · 2021

1 result

The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.

Dekkers IA, Bizino MB, Paiman EHM, Smit JW, Jazet IM, de Vries APJ, Lamb HJ

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation5 Dec 2020Cited by 15 (Europe PMC)

PMID33293204 (opens in a new tab)DOI10.1053/j.jrn.2020.09.006 (opens in a new tab)PepBankPUB-33293204
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

ObjectiveEctopic lipid accumulation in the kidney (fatty kidney) is a potential driver of diabetic kidney disease, and tight glycemic control can reduce risk of diabetic nephropathy. We assessed whether glycemic control influences renal triglyceride content (RTGC). Furthermore, we compared glucagon-like peptide-1 receptor agonist liraglutide versus standard glucose-lowering therapy.Design and methodsIn this single-center parallel-group trial, patients with type 2 diabetes mellitus were randomized to liraglutide or placebo added to standard care (metformin/sulfonylurea derivative/insulin). Changes in RTGC after 26 weeks of glycemic control measured by proton spectroscopy and difference in RTGC between treatment groups were analyzed.ResultsFifty patients with type 2 diabetes mellitus were included in the baseline analysis (mean age, 56.5 ± 9.1 years; range, 33-73 years; 46% males). Seventeen patients had baseline and follow-up measurements. Mean glycated hemoglobin was 7.8 ± 0.8%, which changed to 7.3 ± 0.9% after 26 weeks of glycemic control irrespective of treatment group (P = .046). Log-transformed RTGC was -0.68 ± 0.30% and changed to -0.83 ± 0.32% after 26 weeks of glycemic control irrespective of treatment group (P = .049). A 26-week-to-̶baseline RTGC ratio (95% confidence interval) was significantly different between liraglutide (-0.30 [-0.50, -0.09]) and placebo added to standard care (-0.003 [-0.34, 0.34]) (P = .04).ConclusionIn this exploratory study, we found that 26 weeks of glycemic control resulted in lower RTGC, in particular for liraglutide; however, larger clinical studies are needed to assess whether these changes reflect a true effect of glycemic control on fatty kidney.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the 26-week change in renal triglyceride content differed significantly between liraglutide and placebo added to standard care, with a decrease on liraglutide.

    In plain wordsIn adults with type 2 diabetes, kidney fat fell with liraglutide but not with placebo, in a small exploratory trial.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in renal triglyceride content (RTGC) at 26 weeks
    Study

    n = 17

    Comparator
    Placebo added to standard care
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    A 26-week-to-̶baseline RTGC ratio (95% confidence interval) was significantly different between liraglutide (-0.30 [-0.50, -0.09]) and placebo added to standard care (-0.003 [-0.34, 0.34]) (P = .04).
    2 context sentences
    Summary · context
    In this single-center parallel-group trial, patients with type 2 diabetes mellitus were randomized to liraglutide or placebo added to standard care (metformin/sulfonylurea derivative/insulin).
    Summary · context
    Seventeen patients had baseline and follow-up measurements.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02660047

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

Leiden University Medical Centern = 51Aug 2015 to 9 Mar 2018

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 21 Mar 2018
CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.